Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Neoplasms 2Breast Neoplasms 2Wounds and Injuries 1Stroke 1Stomach Neoplasms 1Spinal Cord Injuries 1Rectal Neoplasms 1Pain, Postoperative 1Muscular Atrophy 1Muscle Spasticity 1Low Anterior Resection Syndrome 1Hereditary leiomyomatosis and renal cell cancer 1Ganglion Cysts 1Esophageal Neoplasms 1Cluster Headache 1Carcinoma, Renal Cell 1Breast Diseases 1Brain Injuries 1

Interventions

Fluorouracil 155Oxaliplatin 133Leucovorin 124Capecitabine 90Irinotecan 88Radiotherapy 63Bevacizumab 61Cetuximab 38Folfox protocol 25Panitumumab 21Neoadjuvant Therapy 21Surgical Procedures, Operative 19Chemotherapy, Adjuvant 15Radiation 13Floxuridine 13Erlotinib Hydrochloride 13Early Intervention, Educational 13IFL protocol 11Drug Therapy 11Proctectomy 10Magnetic Resonance Spectroscopy 10Counseling 10Surveys and Questionnaires 8Sorafenib 8Psychiatric Rehabilitation 8Gene Expression Profiling 8Radiotherapy, Intensity-Modulated 7Immunohistochemistry 7Gemcitabine 7Celecoxib 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Rectal Neoplasms × Botulinum Toxins, Type A × Clear all
NCT01589471 2018-02-12

The Value of Botox-A for Management of Low Anterior Resection Syndrome

Centre hospitalier de l'Université de Montréal (CHUM)

Phase 2 Completed
23 enrolled
Gastrointestinal

Low Anterior Resection Syndrome, Rectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡